Please assess the completion status of the following clinical trial:

Trial Title: DEfibrillators To REduce Risk by MagnetIc ResoNance Imaging Evaluation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Randomized Arm~1. Evidence of Coronary Artery Disease (CAD)a.~2. Evidence of prior Myocardial Infarction defined by either:~   A. Clinical history of prior myocardial infarction OR B. Mild-moderate systolic LV dysfunction with an EF ≤50%~3. LVEF\>35% by any current standard evaluation technique (e.g., echocardiogram, MUGA, angiography).~   • Patients who have an EF between 30-35% and NYHA Class I heart failure who do not have a history of ventricular tachyarrhythmias, or inducible ventricular tachycardia during electrophysiological (EP) testing can be enrolled (Target Population).~4. CE-MRI measure of infarct mass \> 10% of LV mass (as measured by the MRI core lab)~   • If CE-MRI performed ≤ 40 days after myocardial infarction infarct mass must be ≥ 15% of the LV mass.~5. Patients aged 18 years or above~   1. CAD will be confirmed by evidence of one of the following three (3) criteria 1) Prior myocardial infarction, 2) Significant stenosis of a major epicardial vessel (\>50% proximal or 70% distal) by coronary angiography, 3) Prior revascularization (percutaneous coronary intervention or coronary artery bypass surgery. Patients may not be randomized until 90 days after revascularization.~  2. MI should be documented by the presence of two (2) of the following three (3) criteria: 1) Symptoms consistent with myocardial infarction (i.e. chest pain, shortness of breath), 2) Q-waves on electrocardiogram and 3) Elevated cardiac enzymes (CPK elevation \> two times or troponin elevation \> three times the upper limit of normal for the lab). Patients may not be randomized until 40 days after myocardial infarction.~Exclusion Criteria~1. History of cardiac arrest or spontaneous or inducible sustained VT (15 beats or more at a rate of 120 BPM or greater)\*~2. Unexplained syncope~3. Need for revascularization based on investigator's clinical assessment within the next 12 months (patients may be reevaluated 90 days after revascularization)~4. Currently implanted permanent pacemaker and/or pacemaker/ICD lead~5. Contraindication to a ICD implant (i.e. inadequate venous access, bleeding disorder)~6. Acute or chronic severe renal insufficiency (\< 30mL/min/1.73m2); acute renal insufficiency of any severity due to hepato-renal syndrome~7. Current or planned renal or liver transplant~8. End stage renal disease on hemodialysis or peritoneal dialysis~9. Contraindication to CE-MRI or history of allergy to gadolinium-based contrast dye~10. Metal fragments in the eyes or face, implantation of any electronic devices such as (but not limited to) cardiac pacemakers, cardiac defibrillators, cochlear implants or nerve stimulators, surgery on the blood vessels of the brain, body piercing~11. Recent MI (\<40 days) or revascularization (\<90 days)~12. CVA within 90 days~13. Antiarrhythmic drug therapy for ventricular arrhythmias~14. New York Heart Association CHF functional class IV at enrollment~Non-Investigational Registry Inclusion Criteria~* Evidence of CAD a with either a history of prior myocardial infarction OR any LV dysfunction~* Evidence of LV dysfunction (ejection fraction) as measured by any current standard screening technique (e.g., echocardiogram, MUGA, angiography).c~* Clinical CE-MRI within the past 12 months (scheduled or completed)~* Patients aged 18 years or above~* CAD will be confirmed by evidence of one of the following three (3) criteria 1) Prior myocardial infarction, 2) Significant stenosis of a major epicardial vessel (\>50% proximal or 70% distal) by coronary angiography, 3) Prior revascularization (percutaneous coronary intervention or coronary artery bypass surgery.~* MI should be documented by the presence of two (2) of the following three (3) criteria: 1) Symptoms consistent with myocardial infarction (i.e. chest pain, shortness of breath), 2) Q-waves on electrocardiogram and 3) Elevated cardiac enzymes (CPK elevation \> two times or troponin elevation \> three times the upper limit of normal for the lab).~* Patients can be enrolled in the registry even if they have received or are about to receive an ICD for primary prevention.~Exclusion Criteria~* History of cardiac arrest or spontaneous or inducible sustained VT (15 beats or more at a rate of 120BPM or greater)\*~* Contraindication to CE-MRI or history of allergy to gadolinium-based contrast~* Spontaneous arrhythmia that precludes assessment by cardiac MRI~* Acute or chronic severe renal insufficiency (\<30mL/min/1.73m2); acute renal insufficiency of any severity due to hepato-renal syndrome.~* Current or planned renal or liver transplant~* End stage renal disease on hemodialysis or peritoneal dialysis~* Metal fragments in the eyes or face, implantation of any electronic devices such as (but not limited to) cardiac pacemakers, cardiac defibrillators, cochlear implants or nerve stimulators, surgery on the blood vessels of the brain , body piercing~* Uninterpretable MRI images by core lab criteria~* Any condition other than cardiac disease that, in the investigator's judgment, would seriously limit life expectancy (poor 6-month survival)~* Marked valvular heart disease requiring surgical intervention~* Current alcohol or drug abuse~* Participating in other trials with an active treatment arm (not to exclude patients who are in trials of diagnostic techniques or approved therapies)~* Unwilling or unable to provide informed consent \*Exception: Cardiac arrest or spontaneous VT that occurs during the acute MI event will not be considered an exclusion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ICD Group (Type: EXPERIMENTAL): ICD (Implantable Cardioverter Defibrillator)
- Control Group (Type: OTHER): Medial Therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).